Matthew MacKay

Matthew MacKay

Auto-generated profile, based on publicly available information

Matthew MacKay

Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California. 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Blood
Verified
Journal Article
Open access
PDF file
KMKenneth P. Micklethwaite
Kenneth P. Micklethwaite
KGKavitha Gowrishankar
Kavitha Gowrishankar
BGBrian S. Gloss
Brian S. Gloss
ZLZiduo Li
Ziduo Li
JSJanine A. Street
Janine A. Street
EBEmily Blyth
Emily Blyth
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem cell transplant. To overcome the cost and transgene-capacity limitations of traditional viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, 1 patient developed a gradually enlarging retroperitoneal tumor due to a CAR-expressing CD4+ T-cell lymphoma. Screening of other patients led to the detection, in an asymptomatic patient, of a second CAR T-cell tumor in thoracic para-aortic lymph nodes. Analysis of the first lymphoma showed a high transgene copy number, but no insertion into typical oncogenes. There were also structural changes such as altered genomic copy number and point mutations unrelated to the insertion sites. Transcriptome analysis showed transgene promoter–driven upregulation of transcription of surrounding regions despite insulator sequences surrounding the transgene. However, marked global changes in transcription predominantly correlated with gene copy number rather than insertion sites. In both patients, the CAR T-cell–derived lymphoma progressed and 1 patient died. We describe the first 2 cases of malignant lymphoma derived from CAR gene–modified T cells. Although CAR T cells have an enviable record of safety to date, our results emphasize the need for caution and regular follow-up of CAR T recipients, especially when novel methods of gene transfer are used to create genetically modified immune therapies. This trial was registered at www.anzctr.org.au as ACTRN12617001579381.

11 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
Christopher MasonChristopher Mason
Christopher Mason
JGJames Lauer Green
James Lauer Green
KONSTANTINOS ADAMOPOULOSKONSTANTINOS ADAMOPOULOS
KONSTANTINOS ADAMOPOULOS
EAEvan E. Afshin
Evan E. Afshin
JBJordan J. Baechle
Jordan J. Baechle
ABAfshin Beheshti
Afshin Beheshti
The recent acceleration of commercial, private, and multi-national spaceflight has created an unprecedented level of activity in low Earth orbit (LEO), concomitant with the highest-ever number of crewed missions entering space and preparations for exploration-class (>1 year) missions. Such rapid advancement into space from many new companies, countries, and space-related entities has enabled a“Second Space Age.” This new era is also poised to leverage, for the first time, modern tools and methods of molecular biology and precision medicine, thus enabling precision aerospace medicine for the crews. The applications of these biomedical technologies and algorithms are diverse, encompassing multi-omic, single-cell, and spatial biology tools to investigate human and microbial responses to spaceflight. Additionally, they extend to the development of new imaging techniques, real-time cognitive assessments, physiological monitoring, and personalized risk profiles tailored for astronauts. Furthermore, these technologies enable advancements in pharmacogenomics (PGx), as well as the identification of novel spaceflight biomarkers and the development of corresponding countermeasures. In this review, we highlight some of the recent biomedical research from the National Aeronautics and Space Administration (NASA), Japan Aerospace Exploration Agency (JAXA), European Space Agency (ESA), and other space agencies, and also detail the commercial spaceflight sector’s (e.g. SpaceX, Blue Origin, Axiom, Sierra Space) entrance into aerospace medicine and space biology, the first aerospace medicine biobank, and the myriad upcoming missions that will utilize these tools to ensure a permanent human presence beyond LEO, venturing out to other planets and moons.

6 June 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
MLMINETTA LIU
MINETTA LIU
MMMatthew MacKay
Matthew MacKay
MKMatthew Kase
Matthew Kase
APAneta Piwowarczyk
Aneta Piwowarczyk
CLChristine Lo
Christine Lo
BPBen Ho Park
Ben Ho Park
PURPOSE: Tissue-based next-generation sequencing (NGS) in metastatic breast cancer (mBC) is limited by the inability to noninvasively track tumor evolution. Cell-free DNA (cfDNA) NGS has made sequential testing feasible; however, the relationship between cfDNA and tissue-based testing in mBC is not well understood. Here, we evaluate concordance between tissue and cfDNA NGS relative to cfDNA sampling frequency in a large, clinically annotated mBC data set.METHODS: Tempus LENS was used to analyze deidentified records of mBC cases with Tempus xT (tissue) and xF (cfDNA) sequencing results. Then, various metrics of concordance were assessed within overlapping probe regions of the tissue and cfDNA assays (104 genes), focusing on pathogenic variants. Variant allele frequencies of discordant and concordant pathogenic variants were also compared. Analyses were stratified by mBC subtype and time between tests.RESULTS: Records from 300 paired tissue and liquid biopsies were analyzed. Median time between tissue and blood collection was 78.5 days (standard deviation = 642.99). The median number of pathogenic variants/patient was one for cfDNA and two for tissue. Across the cohort, 77.8% of pathogenic tissue variants were found in cfDNA and 75.7% of pathogenic cfDNA variants were found in tissue when tests were ≤ 7 days apart, which decreased to 50.3% and 51.8%, respectively, for > 365 days. Furthermore, the median patient-level variant concordance was 67% when tests were ≤7 days apart and 30%-37% when > 30 days. The median variant allele frequencies of discordant variants were generally lower than those of concordant variants within the same time frame.CONCLUSION: We observed high concordances between tissue and cfDNA results that generally decreased with longer durations between tests. Thus, cfDNA NGS reliably measures tissue genomics and is likely beneficial for longitudinal monitoring of molecular changes in mBC.

11 July 2024 in Cancer Research
Verified
Journal Article
Closed access
OIOihana Iriondo
Oihana Iriondo
DMDesirea Mecenas
Desirea Mecenas
YLYilin Li
Yilin Li
CCChristopher R. Chin
Christopher R. Chin
ATAmal Thomas
Amal Thomas
MYMin Yu
Min Yu
Hypoxia is a common feature of many solid tumors due to aberrant proliferation and angiogenesis that is associated with tumor progression and metastasis. Most of the well-known hypoxia effects are mediated through hypoxia-inducible factors (HIF). Identification of the long-lasting effects of hypoxia beyond the immediate HIF-induced alterations could provide a better understanding of hypoxia-driven metastasis and potential strategies to circumvent it. Here, we uncovered a hypoxia-induced mechanism that exerts a prolonged effect to promote metastasis. In breast cancer patient-derived circulating tumor cell lines and common breast cancer cell lines, hypoxia downregulated tumor-intrinsic type I IFN signaling and its downstream antigen presentation (AP) machinery in luminal breast cancer cells, via both HIF-dependent and HIF-independent mechanisms. Hypoxia induced durable IFN/AP suppression in certain cell types that was sustained after returning to normoxic conditions, presenting a “hypoxic memory” phenotype. Hypoxic memory of IFN/AP downregulation was established by specific hypoxic priming, and cells with hypoxic memory had an enhanced ability for tumorigenesis and metastasis. Overexpression of IRF3 enhanced IFN signaling and reduced tumor growth in normoxic, but not hypoxic, conditions. The histone deacetylase inhibitor entinostat upregulated IFN targets and erased the hypoxic memory. These results point to a mechanism by which hypoxia facilitates tumor progression through a long-lasting memory that provides advantages for circulating tumor cells during the metastatic cascade. Significance: Long-term cellular memory of hypoxia leads to sustained suppression of tumor-intrinsic type I IFN signaling and the antigen presentation pathway that facilitates tumorigenesis and metastasis. See related commentary by Purdy and Ford, p. 3125

21 January 2022 in Foot & Ankle Orthopaedics
Verified
Journal Article
Open access
SFSpencer Falcon
Spencer Falcon
TMThomas J. McCormack
Thomas J. McCormack
MMMatthew Mackay
Matthew Mackay
ATArmin Tarakemeh
Armin Tarakemeh
SMScott Mullen
Scott Mullen
BVBryan G. Vopat
Bryan G. Vopat
Category: Ankle Introduction/Purpose: Tibiofibular Syndesmosis injuries are commonly misdiagnosed due to their unreliable projection on plain films. Many studies have striven to establish baseline measurements of the distal tibial and fibular articulation. While cadaver, MRI, ultrasound, and non-weight bearing computer tomography (CT) have been utilized, weight bearing CT (WBCT) scans are a relatively new imaging modality that has not yet been utilized to establish reproducible and widely-referenced baseline anatomic positions. The hypotheses of this study are: 1. Standing, weight bearing CT scan will allow for evaluation and measurement of the tibio-fibular syndesmosis. 2. There will be no side to side variation or sex-based differences in syndesmosis measurements. Methods: A retrospective chart review was conducted using the electronic medical record. Inclusion criteria was applied as follows: Patients who have undergone weight bearing CT of the bilateral lower extremities from 2018 to 2020. One hundred twenty ankle CT scans were acquired for measurements. Measurements were collected by two independent reviewers twice in order to achieve inter- and intra-reliability. The measurements were then analyzed in order to establish a baseline for normal anatomy, compare injured to non-injured side, and observe any sex-based differences. Results: Measurements of uninjured legs were utilized to define normal parameters for tibiofibular syndesmosis on weight bearing CT. Averages were found for measurements of anterior incisura 3.2mm (SD=1.1mm), middle incisura 3.9mm (SD=1.1mm), posterior incisura 5.6mm (SD=1.7mm), alpha angle 16.3° (SD=6.3°), medial clear space 2.2mm (SD=0.6mm).Patients with syndesmotic injuries had significantly larger measurements for anterior (p<0.0001), middle (p=0.0007), and posterior incisura (p=0.002) when compared to uninjured ankles. Males had significantly higher medial clear space widening (p=0.0012) compared to female patients. Anterior incisura (p <0.0001), posterior incisura (p=0.0005) were found to significantly decrease as age increased. Conclusion: This study aims to assist in defining baseline anatomic measurements for syndesmotic parameters. The values and comparisons obtained were able to reinforce that weight bearing CT is valuable in identifying subtle injuries to the TFS while also demonstrating that there is male-to-female and age-related differences that should be kept in mind when radiographically evaluating imaging studies of injured patients.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
MMMatthew MacKay
Matthew MacKay
JDJoshua Drews
Joshua Drews
BDBonnie V. Dougherty
Bonnie V. Dougherty
DHDuane Hassane
Duane Hassane
CMChris Mason
Chris Mason
JGJustin Guinney
Justin Guinney
Background: Actionable genomic alterations can be identified through either a biopsy of solid tissue or the detection of circulating tumor DNA from plasma. Little is known about the concordance rates of pathogenic variants between cell free DNA (cfDNA) and solid biopsies, including how concordance varies over time, by cancer type, or by treatment. Here we examine the concordance of pathogenic variants identified in solid tissue biopsies to patient-matched cfDNA biopsies in one of the largest pan-cancer datasets. Methods: De-identified records of cfDNA (xF) and solid (xT) biopsies were analyzed in 2418 stage 4 patients across 5 cancer types: breast (N=459), colon (N= 564), non-small cell lung cancer (NSCLC) (N=750), pancreatic (N=353) and prostate (N=292). Patients were required to have ≥1 pathogenic variant detected in the solid biopsy and a cfDNA biopsy occurring on the same day or after the solid biopsy. Pathogenic SNVs and indels within overlapping probe regions of xF and xT meeting assay limits of detection were included for analysis. Only one cfDNA and solid biopsy were analyzed per patient. Results: Overall, the total number of pathogenic variants identified in solid tissue and cfDNA were highly similar within each cancer type (breast 881 vs 831; colon 1983 vs 1673; NSCLC 1672 vs 1470; pancreas 873 vs 703; prostate 480 vs 384; solid biopsy vs. cfDNA, respectively). Subsetting to patients with ≥1 pathogenic variant in both assays (77%), >40% of patients had additional pathogenic variants identified in their cfDNA which were not found in their solid tissue profiling. Of these subsetted patients which also had cfDNA collected >1 year after their solid biopsy, >25% of NSCLC and >20% of breast cancer patients had mutually exclusive variants (all solid tissue variants were undetectable while new pathogenic variants were found in cfDNA). When comparing samples taken between one week and over one year from each other, the percentage of solid tissue variants identified in cfDNA decreased in a time dependent manner (breast 73% vs. 48%; colon 76% vs. 55%; NSCLC 75% vs. 43%; pancreas 76% vs. 36%; prostate 72% vs. 42%; ≤1 week vs. >1 year, respectively). Conclusions: To our knowledge, this is the largest dataset of matched solid and cfDNA biopsies. >40% of patients with ≥1 pathogenic variants in both assays had additional pathogenic variants found only in their cfDNA. Further, cfDNA was capable of identifying the majority (>70%) of solid tissue variants when samples were taken within one week of each other, though this concordance decreased with time. This data strongly supports the use of matched solid and cfDNA testing, and further exploration of the clinical utility of cfDNA to identify pathogenic variants over the course of a patient’s disease. We will continue to acquire more data and results will be updated before presentation. Citation Format: Matthew MacKay, Joshua Drews, Bonnie V. Dougherty, Duane Hassane, Chris Mason, Gaurav Khullar, Calvin Chao, Joel Dudley, Kimberly L. Blackwell, Nike T. Beaubier, Justin Guinney. Temporal concordance rates of pathogenic variants in liquid biopsies taken after solid tissue NGS profiling in a real-world pan-cancer cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 62.